艳山姜化学成分及药理作用研究进展.pdf

2010; 26(5) 179 48 , , , . CYP3A1/2 CYP3A4/5 expression as abiomarker of outcome in osteosarcoma. JC lin On , 2007; 22(9) 598~ 602 col. 2003; 21( 13) 2481~ 2485 49 ,, , . 56 Characterization of hepatic cytochrome p4503A activity in patientsw ith P450. , 2006; 12( 12) 48~ 50 endstage renal disease. Clin PharmacolTher, 2003; 73( 5) 427~ 434 50 , , , . CYP3A l/2 57 R ivory LP, Slaviero KA, C larke SJHepatic cytochrome P450 3A drug mRNA, 2007; 10( 6) 515~ 518 metabolism is reduced in cancer patientswho have an acutephase response. 51 . . 2005, Br J Cancer, 2002; 87( 3) 277~ 280 19( 3) 175 58 roningerE, M eeuwsende BoerT, Koornans P, et a1. Pharmacokinetics 52 ,, , . P450 of vincristinemonotherapy in childhood acute lymphoblastic leukem ia, 2002; mRNA. , 2004; 29(4) 366~ 370 52( 1) 113~ 118 53 W itte JS. enetic polymorphisms and prostate cancer risk. W orld J 59 B isogno , CowieF, BoddyA, el a1. H ighdose cyclosporinew ith etopo U rol, 2004; 21( 6) 414~ 423 side toxicity and pharmacokinetic interaction in children w ith solid tumours, 54 PlummerSJ, ContiDV, Paris PL, et al. CYP3A4 and CYP3A5 geno 1998; 77( 12) 2304~ 2309 types, haplotypes, and risk of prostate cancer. CancerEpidemiolBiomarkers 60 , . . Prev, 2003, 12(9) 928~ 932 , 2002; 15( 1) 74~ 77 55 Dhaini HR, Thomas D , iordano TJ, et al. Cytochrome P450 * * * 张彦燕, 沈祥春